Membranoproliferative glomerulonephritis in a patient with congenital deficiency of the third component of complement: effect of treatment with plasma. 1989

J J Roord, and R A van Diemen-van Steenvoorde, and H J Schuurman, and G T Rijkers, and B J Zegers, and F H Gmelig Meyling, and J W Stoop
University Hospital for Children and Youth, Het Wilhelmina Kinderziekenhuis, Utrecht, The Netherlands.

A 21-year-old woman with a known congenital complement component 3 (C3) deficiency developed membranoproliferative glomerulonephritis. The kidney biopsy exhibited deposits of immunoglobulins and complement components despite the C3 deficiency. The administration of fresh frozen plasma was without therapeutic benefit. Corticosteroid treatment was followed by an improvement in kidney function.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D010949 Plasma The residual portion of BLOOD that is left after removal of BLOOD CELLS by CENTRIFUGATION without prior BLOOD COAGULATION. Blood Plasma,Fresh Frozen Plasma,Blood Plasmas,Fresh Frozen Plasmas,Frozen Plasma, Fresh,Frozen Plasmas, Fresh,Plasma, Blood,Plasma, Fresh Frozen,Plasmas,Plasmas, Blood,Plasmas, Fresh Frozen
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D001803 Blood Transfusion The introduction of whole blood or blood component directly into the blood stream. (Dorland, 27th ed) Blood Transfusions,Transfusion, Blood,Transfusions, Blood
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001706 Biopsy Removal and pathologic examination of specimens from the living body. Biopsies
D015432 Glomerulonephritis, Membranoproliferative Chronic glomerulonephritis characterized histologically by proliferation of MESANGIAL CELLS, increase in the MESANGIAL EXTRACELLULAR MATRIX, and a thickening of the glomerular capillary walls. This may appear as a primary disorder or secondary to other diseases including infections and autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Various subtypes are classified by their abnormal ultrastructures and immune deposits. Hypocomplementemia is a characteristic feature of all types of MPGN. C3G Complement 3 Glomerulopathy,Complement 3 Glomerulopathies,Complement 3 Glomerulopathy,Glomerulonephritis, Mesangiocapillary,MPGN Membranoproliferative Glomerulonephritis,Membranoproliferative Glomerulonephritis,Mesangiocapillary Glomerulonephritis,DDD MPGNII,Dense Deposit Disease,Glomerulonephritis, Hypocomplementemic,MPGNII,Membranoproliferative Glomerulonephritis Type II,Membranoproliferative Glomerulonephritis, Type I,Membranoproliferative Glomerulonephritis, Type II,Membranoproliferative Glomerulonephritis, Type III,Mesangiocapillary Glomerulonephritis, Type I,Mesangiocapillary Glomerulonephritis, Type II,Subendothelial Membranoproliferative Glomerulonephritis,Type II MPGN,DDD MPGNIIs,Glomerulonephritides, MPGN Membranoproliferative,Glomerulonephritides, Membranoproliferative,Glomerulonephritis, MPGN Membranoproliferative,Glomerulopathies, Complement 3,Glomerulopathy, Complement 3,Hypocomplementemic Glomerulonephritides,Hypocomplementemic Glomerulonephritis,MPGN Membranoproliferative Glomerulonephritides,MPGN, Type II,MPGNII, DDD,MPGNIIs,Membranoproliferative Glomerulonephritides,Membranoproliferative Glomerulonephritides, MPGN,Membranoproliferative Glomerulonephritis, MPGN,Membranoproliferative Glomerulonephritis, Subendothelial,Mesangiocapillary Glomerulonephritides,Type II MPGNs

Related Publications

J J Roord, and R A van Diemen-van Steenvoorde, and H J Schuurman, and G T Rijkers, and B J Zegers, and F H Gmelig Meyling, and J W Stoop
September 1991, Clinical immunology and immunopathology,
J J Roord, and R A van Diemen-van Steenvoorde, and H J Schuurman, and G T Rijkers, and B J Zegers, and F H Gmelig Meyling, and J W Stoop
October 2003, Clinical nephrology,
J J Roord, and R A van Diemen-van Steenvoorde, and H J Schuurman, and G T Rijkers, and B J Zegers, and F H Gmelig Meyling, and J W Stoop
May 1977, The American journal of medicine,
J J Roord, and R A van Diemen-van Steenvoorde, and H J Schuurman, and G T Rijkers, and B J Zegers, and F H Gmelig Meyling, and J W Stoop
September 1980, Archives of pathology & laboratory medicine,
J J Roord, and R A van Diemen-van Steenvoorde, and H J Schuurman, and G T Rijkers, and B J Zegers, and F H Gmelig Meyling, and J W Stoop
November 1983, Kidney international,
J J Roord, and R A van Diemen-van Steenvoorde, and H J Schuurman, and G T Rijkers, and B J Zegers, and F H Gmelig Meyling, and J W Stoop
April 1983, The New England journal of medicine,
J J Roord, and R A van Diemen-van Steenvoorde, and H J Schuurman, and G T Rijkers, and B J Zegers, and F H Gmelig Meyling, and J W Stoop
June 2003, Clinical and experimental nephrology,
J J Roord, and R A van Diemen-van Steenvoorde, and H J Schuurman, and G T Rijkers, and B J Zegers, and F H Gmelig Meyling, and J W Stoop
January 2005, Clinical laboratory,
J J Roord, and R A van Diemen-van Steenvoorde, and H J Schuurman, and G T Rijkers, and B J Zegers, and F H Gmelig Meyling, and J W Stoop
May 2008, Molecular immunology,
J J Roord, and R A van Diemen-van Steenvoorde, and H J Schuurman, and G T Rijkers, and B J Zegers, and F H Gmelig Meyling, and J W Stoop
January 1985, American journal of kidney diseases : the official journal of the National Kidney Foundation,
Copied contents to your clipboard!